MRNA to PFE: Top vaccine stocks to watch amid fresh covid surge

Image Source: © Michalrojek | Megapixl.com

Highlights:

  • Moderna, Inc. (NASDAQ: MRNA) will report its first-quarter fiscal 2022 results on May 4.
  • Pfizer, Inc’s (NYSE: PFE) revenue jumped 105% YoY in Q4, FY21.
  • Novavax, Inc. (NASDAQ: NVAX) expects revenue between US$4 billion and US$5 billion in fiscal 2022.

Vaccine manufacturers will have a busy summer ahead as a new Covid-19 variant is wreaking havoc. According to the US Centers for Disease Control and Prevention (CDC), around 86% of the new cases in the US in recent days were caused by the Omicron subvariant BA.2.

In China, the rapid spread of the subvariant has forced authorities to enforce strict restrictions in the affected areas. The country’s financial hub Shanghai has clamped fresh lockdowns to stop its spread, the worst outbreak since 2020. Meanwhile, vaccine makers like Pfizer, Moderna, etc., have recommended using a fourth covid dose to protect people against the virus.

Here we explore some of the vaccine makers bracing for busy months ahead, conducting research and possibly coming up with booster dose against BA.2.

Also Read: Is Ethereum (ETH) rallying on Merge update? When is it happening?

Moderna, Inc. (NASDAQ: MRNA)

Moderna is a pharmaceutical and biotechnology firm focused on developing RNA therapeutics, especially mRNA vaccines. It is based in Cambridge, Massachusetts.

The shares of the company traded at US$166.645 at 12:23 pm ET on April 14, down 1.78% from their closing price of April 13. Its stock value decreased by 27.82% YTD.

The firm has a market cap of US$67.03 billion, a P/E ratio of 5.88, and a forward one-year P/E ratio of 6.30. Its EPS is US$28.29.

The 52-week highest and lowest stock prices were US$497.49 and US$122.01, respectively. Its trading volume was 6,735,280 on April 13. The company will report its first-quarter fiscal 2022 financial results on May 4, before the opening bell.

The company's total revenue was US$7.21 billion in Q4, FY21, while its net income came in at US$4.86 billion, or US$11.29 per diluted share. For fiscal 2021, the company's total revenue was US$18.47 billion, as compared to US$803 million in FY20.

Also Read: Why is VeThor Token (VTHO) crypto jumped 299% today?

Source: ©2022 Kalkine Media®

Pfizer, Inc. (NYSE: PFE)

Pfizer is a biotechnology and pharmaceutical firm engaged in discovering, developing, and manufacturing biopharmaceutical products. It is based in New York.

The stock of the company traded at US$53.296 at 12:29 pm ET on April 14, up 0.37% from its previous closing price. The PFE stock fell 6.27% YTD.

The market cap of the company is US$301.02 billion, the P/E ratio is 13.84, and the forward one-year P/E ratio is 7.29. Its EPS is US$3.85.

The stock saw the highest price of US$61.71 and the lowest price of US$36.96 in the last 52 weeks. Its share volume on April 13 was 15,777,810.

The company's revenue increased by 105% YoY to US$23.83 billion in Q4, FY21, while its net income came in at US$3.39 billion, or US$0.59 per diluted share. For fiscal 2021, the company's revenue rose 95% YoY to US$81.28 billion.

Also Read: Why is metaverse-focused Meta Ruffy (MR) crypto rising?

AstraZeneca PLC (NASDAQ: AZN)

AstraZeneca is a pharmaceutical and biotechnology firm based in Cambridge, the United Kingdom. It specializes in discovering, developing, and manufacturing prescription medicines to treat diseases related to oncology, respiratory, immunology, etc.

The shares of the company traded at US$68.875 at 12:36 pm ET on April 14, down 0.14% from their closing price of April 13. Its stock value increased by 18.28% YTD.

The firm has a market cap of US$213.60 billion, a P/E ratio of 492.36, and a forward one-year P/E ratio of 20.84. Its EPS is US$0.14.

The 52-week highest and lowest stock prices were US$71.70 and US$49.74, respectively. Its trading volume was 6,304,742 on April 13.

The company's total revenue increased by 62% YoY to US$12.01 billion in Q4, FY21, while its operating loss came in at US$292 million. For fiscal 2021, its revenue increased by 41% YoY to US$37.41 billion.

Also Read: What is NEXO’s crypto-backed credit card? How is Mastercard involved?

BioNTech SE (NASDAQ: BNTX)

BioNTech is another popular name among the Covid-19 vaccine manufacturers. It is a Mainz, Germany-based biotechnology company.

The stock of the company traded at US$175.84 at 12:52 pm ET on April 14, down 1.97% from its previous closing price. The BNTX stock declined 22.63% YTD.

The market cap of the company is US$43.37 billion, the P/E ratio is 3.76, and the forward one-year P/E ratio is 5.64. Its EPS is US$46.76.

The stock saw the highest price of US$464.00 and the lowest price of US$121.32 in the last 52 weeks. Its share volume on April 13 was 1,947,585.

The company reported a revenue of €5.53 billion (US$5.98 billion) in Q4, FY21, while its net profit was €3.16 billion (US$3.42 billion). For fiscal 2021, the company's net revenue was €18.97 billion (US$20.52 billion).

Also Read: Why is GMX crypto gaining attention? 

 

Novavax, Inc. (NASDAQ: NVAX)

Novavax is a biotechnology firm focused on developing vaccines to prevent serious infectious diseases. It is based in Gaithersburg, Maryland.

The shares of the company traded at US$59.10 at 12:57 pm ET on April 14, down 4.94% from their closing price of April 13. Its stock value tumbled 56.49% YTD.

The firm has a market cap of US$4.50 billion and a forward one-year P/E ratio of 2.72. Its EPS is US$-23.29.

The 52-week highest and lowest stock prices were US$277.80 and US$56.67, respectively. Its trading volume was 3,382,522 on April 13.

The company's total revenue was US$222.20 million in Q4, FY21, while its net loss came in at US$846.28 million. For fiscal 2021, the company's total revenue was US$1.14 billion.

For fiscal 2022, the company expects its revenue to be between US$4 billion and US$5 billion.

Also Read: Why is Polygon (MATIC) rising? Does it have a Robinhood connection?

Bottom line:

Vaccine makers saw record sales last year due to the Covid-19 pandemic. But as a major segment of the US population has been vaccinated and the initial rush for vaccines eased, most US healthcare firms might be looking for sales in the developing nations in Asia and Africa. The emergence of the Omicron subvariant may also open new revenue opportunities. However, investors should exercise due diligence before investing in stocks, given the market volatility.


 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use on